ArticleIndian journal of endocrinology and metabolism
Magnitude and Determinants of Weight Loss Response to GLP-1/GIP Receptor Agonists in India: A Real-World Time-to-Event Analysis.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Obesity and type 2 diabetes (T2D) are rapidly increasing in India. Although newer glucagon-like peptide/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonists have demonstrated considerable efficacy in weight loss, real-world evidence from the Indian population is lacking. This study evaluated the response to semaglutide and tirzepatide in overweight/obese individuals in routine clinical practice. Methods: This retrospective cohort study was conducted at a tertiary centre in New Delhi, India. Data from 150 overweight/obese participants (74 with T2D, 76 without T2D) treated with semaglutide/tirzepatide over 6 months were analysed. Outcomes included percentage weight loss, achievement of predefined weight-loss thresholds, time-to-event (≥10% weight loss), and determinants of time-to-event. Non-parametric tests and Cox proportional hazard regression were used for analysis. Results: The median weight loss was 8.2% (4.93-13.66). Participants without T2D achieved significantly greater weight loss than those with T2D (11.21% vs 5.48%, Conclusion: In this real-world Indian cohort, GLP-1/GIP receptor agonists were effective means for weight loss in obese adults, with or without T2D. The magnitude and speed of weight loss outcomes may help in personalising therapy and setting expectations when initiating newer GLP-1/GIP receptor agonists.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.